Shots:
- Eli Lilly has reported that Foundayo is now available in the US, along with lifestyle intervention for obese/overweight adults with weight-related medical problems. Foundayo is now available via LillyDirect and telehealth, with US retail rollout starting today
- Approval was backed by the ATTAIN program, including ATTAIN-1 (n= 3127), where Foundayo showed weight loss of 27.3 lbs (12.4%) vs 2.2 lbs (0.9%) with PBO at the highest dose, with overall loss of 25 lbs (11.1%) vs 5.3 lbs (2.1%), alongside reductions in CV risk markers across all doses
- To support uptake in the US, Eli Lilly aims to improve access to Foundayo by offering pricing from $25/month (insured), $149/month (self-pay), and approximately $50/month for eligible Medicare Part D patients, starting July 2026
Ref: Eli Lilly | Image: Eli Lilly | Press Release
Related News: Eli Lilly Reports US FDA Approval of Foundayo (Orforglipron) for Weight Loss
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
